Nordic Life Science Platform

The Nordic Life Science Platform (NLSP), with offices in Copenhagen and Shanghai, gives mostly Nordic medtech, healthtech, biotech, and pharma companies a safer, easier, and faster access to the rapidly expanding Chinese healthcare market by taking advantage of the preferential policies and opportunities at the “Hainan Boao Lecheng International Medical Tourism Pilot Zone” (HBL) and “Guangdong-HK-Macao-Great Bay Area” (GBA).

HBL and GBA serve as viable stepping-stones to the rest of the Chinese healthcare market in which the NLSP Step-by-Step Market Entry Model reduces the challenges and time-to-market by offering expert advise and supporting services such as:

Project management, legal assistance, IPR protection, medical expert review, hospital matchmaking, contract negotiations, fast-track approval, CRO appointment & RWD study pre-communication, RWD study implementation & new medical product application, NMPA product registrations, market research, partner search, contact to potential investors, and company establishment.

NLSP cooperates closely with the hospitals at HBL and GBA and Chinese national distributors of medical products that can open doors to the rest of the mainland China market.

NLSP also assists Chinese life science companies interested in investing in and partnering up with Nordic life science companies by identifying and securing potential targets that complement their product portfolios in China or overseas.

Please check www.nlsp.dk for further information and contact details.